Market Summary
USD115.61+0.11
Market Closed0.10%
HZNP Alerts
HZNP Stock Price
HZNP RSI Chart
HZNP Valuation
HZNP Price/Sales (Trailing)
HZNP Profitability
HZNP Fundamentals
HZNP Revenue
HZNP Earnings
Price Action
52 Week Range
60.03115.73
(Low)(High)
Last 7 days
0.3%
Last 30 days
8.9%
Last 90 days
12.7%
Trailing 12 Months
84.6%
HZNP Financial Health
HZNP Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for HZNP
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-06 | SHERMAN JEFFREY W | gifted | - | - | -2,165 | evp and chief medical officer |
2023-05-09 | Himawan Jeff | gifted | - | - | 7,873 | - |
2023-05-09 | Himawan Jeff | gifted | - | - | -7,873 | - |
2023-04-28 | Watkins Thomas | acquired | - | - | 3,913 | - |
2023-04-28 | Witz Pascale | acquired | - | - | 3,913 | - |
2023-04-28 | Witz Pascale | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Shannon James Samuel | acquired | - | - | 3,913 | - |
2023-04-28 | Daniel William F | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Mahony Susan | sold (taxes) | -208,870 | 111 | -1,879 | - |
2023-04-28 | Himawan Jeff | acquired | - | - | 3,913 | - |
Which funds bought or sold HZNP recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | added | 3,462 | 14,148,400 | 14,679,400 | 0.12% |
2023-09-20 | BARCLAYS PLC | reduced | -36.71 | -68,159,000 | 100,710,000 | 0.06% |
2023-09-12 | Farther Finance Advisors, LLC | reduced | -0.1 | -6,575 | 105,730 | 0.02% |
2023-09-11 | BLUEFIN CAPITAL MANAGEMENT, LLC | new | - | 5,921,790 | 5,921,790 | 1.13% |
2023-08-23 | Stonebridge Capital Advisors LLC | unchanged | - | -314 | 5,143 | -% |
2023-08-23 | CTC Alternative Strategies, Ltd. | new | - | 638,699 | 638,699 | 0.80% |
2023-08-22 | COMERICA BANK | new | - | 90,000 | 90,000 | 0.01% |
2023-08-22 | Asset Dedication, LLC | unchanged | - | - | 1,000 | -% |
2023-08-21 | Affinity Asset Advisors, LLC | sold off | -100 | -2,182,800 | - | -% |
2023-08-21 | VisionPoint Advisory Group, LLC | new | - | 41,140 | 41,140 | 0.02% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
HZNP Alerts
Schedule 13G FIlings of Horizon Pharma
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.37% | 21,236,103 | SC 13G/A | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 07, 2023 | blackrock inc. | 6.5% | 14,794,254 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 5.7% | 13,008,024 | SC 13G/A | |
| Feb 11, 2021 | renaissance technologies llc | 3.08% | 6,798,963 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 9.03% | 19,920,258 | SC 13G/A | |
| Feb 08, 2021 | fmr llc | - | 0 | SC 13G | |
| Jan 29, 2021 | blackrock inc. | 6.4% | 14,206,978 | SC 13G/A | |
| Feb 12, 2020 | vanguard group inc | 9.12% | 17,089,414 | SC 13G/A |
Recent SEC filings of Horizon Pharma
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 12, 2023 | 8-K | Current Report | |
| Sep 07, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 8-K | Current Report | |
| Sep 01, 2023 | 8-K | Current Report | |
| Aug 08, 2023 | 10-Q | Quarterly Report | |
| Aug 08, 2023 | 8-K | Current Report | |
| Jul 28, 2023 | 4 | Insider Trading | |
| Jul 28, 2023 | 4 | Insider Trading | |
| Jul 28, 2023 | 4 | Insider Trading | |
| Jul 28, 2023 | 4 | Insider Trading |
Peers (Alternatives to Horizon Pharma)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
LLY | 495.3B | 29.5B | -0.51% | 77.59% | 76.23 | 16.78 | 1.53% | 14.16% |
JNJ | 417.0B | 97.8B | -1.74% | -2.10% | 31.95 | 4.27 | 2.29% | -28.92% |
MRK | 272.8B | 58.3B | -4.46% | 23.17% | 17.88 | 4.63 | 2.00% | -81.24% |
PFE | 184.6B | 77.9B | -10.83% | -26.03% | 8.6 | 2.37 | -23.04% | -26.74% |
BMY | 150.1B | 45.2B | -4.32% | -16.75% | 23.72 | 3.25 | -4.15% | 20.34% |
| MID-CAP | ||||||||
RETA | 6.5B | - | 1.87% | 616.21% | -74.09 | 4.1K | -86.94% | 71.24% |
PRGO | 4.4B | 4.6B | -14.86% | -16.47% | -64.45 | 0.94 | 6.60% | 42.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -14.29% | -1.08 | 2.51 | -0.20% | -204.67% |
SUPN | 1.5B | 634.0M | -12.24% | -14.48% | 35.26 | 2.41 | 0.62% | -24.59% |
INVA | 841.4M | 244.3M | -2.86% | 8.68% | 4.27 | 3.44 | -39.50% | -4.99% |
CRON | 792.7M | 109.5M | 17.51% | -27.27% | -5.52 | 7.24 | -2.66% | -32.13% |
ACRS | 470.6M | 31.2M | -8.53% | -51.99% | -4.47 | 15.1 | 407.54% | -26.47% |
CGC | 462.3M | 453.3M | 100.98% | -69.12% | -0.38 | 1.02 | -16.04% | 55.90% |
OCUL | 252.8M | 54.6M | -17.14% | -44.23% | -2.79 | 4.63 | 9.39% | -179.16% |
ENDP | - | 2.2B | - | - | - | - | -22.39% | 63.59% |
Horizon Pharma News
Returns for HZNP
Cumulative Returns on HZNP
41.9%
10-Year Cumulative Returns
29.0%
7-Year Cumulative Returns
43.8%
5-Year Cumulative Returns
13.9%
3-Year Cumulative Returns
Risks for HZNP
What is the probability of a big loss on HZNP?
50.4%
Probability that Horizon Pharma stock will be more than 20% underwater in next one year
37.3%
Probability that Horizon Pharma stock will be more than 30% underwater in next one year.
14.2%
Probability that Horizon Pharma stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does HZNP drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Horizon Pharma was unfortunately bought at previous high price.
Drawdowns
Financials for Horizon Pharma
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 1.9% | 3,644 | 3,576 | 3,629 | 3,701 | 3,813 | 3,769 | 3,226 | 2,957 | 2,557 | 2,187 | 2,200 | 1,819 | 1,518 | 1,376 | 1,300 | 1,292 | 1,282 | 1,264 | 1,208 | 1,126 | 1,073 |
| Gross Profit | 3.0% | 2,741 | 2,662 | 2,709 | 2,781 | 2,875 | 2,860 | 2,432 | 2,242 | 1,942 | 1,651 | 1,668 | 1,353 | 1,114 | 1,004 | 938 | 926 | 915 | 895 | 816 | 690 | 602 |
| Operating Expenses | 1.1% | 2,228 | 2,203 | 2,091 | 2,104 | 2,027 | 1,963 | 1,889 | 1,692 | 1,494 | 1,305 | 1,178 | 1,049 | 989 | 892 | 811 | 772 | 747 | 741 | 778 | 802 | 802 |
| S&GA Expenses | 2.2% | 1,658 | 1,622 | 1,541 | 1,567 | 1,530 | 1,487 | 1,446 | 1,324 | 1,190 | 1,057 | 973 | 882 | 828 | 773 | 697 | 686 | 676 | 685 | 692 | 685 | 678 |
| R&D Expenses | 10.0% | 516 | 469 | 438 | 422 | 397 | 434 | 345 | 278 | 218 | 159 | 129 | 167 | 161 | 109 | 103 | 94.00 | 91.00 | 87.00 | 83.00 | 94.00 | 91.00 |
| EBITDA | -100.0% | - | 885 | 1,024 | 1,064 | 1,223 | 917 | 736 | 559 | 465 | 492 | 621 | 414 | 180 | 149 | 130 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.25* | 0.28* | 0.29* | 0.32* | 0.24* | 0.23* | 0.19* | 0.18* | 0.22* | 0.28* | 0.23* | 0.12* | 0.11* | 0.10* | - | - | - | - | - | - |
| Interest Expenses | 14.2% | 139 | 122 | 106 | 92.00 | 84.00 | 83.00 | 74.00 | 65.00 | 54.00 | 44.00 | 52.00 | 55.00 | 59.00 | 89.00 | 78.00 | 117 | 106 | 113 | 112 | 107 | 111 |
| Earnings Before Taxes | 18.9% | 444 | 373 | 527 | 584 | 756 | 807 | 463 | 481 | 376 | 263 | 402 | 209 | -5.11 | -18.06 | -20.22 | -4.51 | 40.00 | 30.00 | -83.13 | -234 | -323 |
| EBT Margin | -100.0% | - | 0.10* | 0.15* | 0.16* | 0.20* | 0.21* | 0.14* | 0.16* | 0.15* | 0.12* | 0.18* | 0.11* | 0.00* | -0.01* | -0.02* | - | - | - | - | - | - |
| Net Income | 17.8% | 438 | 372 | 521 | 574 | 765 | 862 | 534 | 552 | 518 | 280 | 390 | 792 | 517 | 592 | 573 | 82.00 | 97.00 | 77.00 | -38.38 | -178 | -275 |
| Net Income Margin | -100.0% | - | 0.10* | 0.14* | 0.16* | 0.20* | 0.23* | 0.17* | 0.19* | 0.20* | 0.13* | 0.18* | 0.44* | 0.34* | 0.43* | 0.44* | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 1,054 | 1,194 | 1,314 | 1,346 | 1,182 | 959 | 810 | 522 | 545 | 386 | 197 | 185 | 173 | 408 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 3.4% | 9,299 | 8,993 | 9,115 | 9,028 | 8,853 | 8,740 | 8,678 | 8,609 | 8,207 | 7,847 | 6,073 | 5,767 | 4,538 | 4,315 | 4,436 | 3,721 | 3,708 | 3,936 | 3,942 | 4,019 | 3,990 |
| Current Assets | 8.9% | 3,922 | 3,603 | 3,653 | 3,412 | 3,203 | 2,948 | 2,800 | 2,414 | 2,175 | 1,831 | 3,070 | 2,732 | 1,489 | 1,414 | 1,686 | 1,479 | 1,402 | 1,560 | 1,546 | 1,339 | 1,235 |
| Cash Equivalents | 6.6% | 2,465 | 2,312 | 2,353 | 2,131 | 1,893 | 1,643 | 1,580 | 1,069 | 812 | 812 | 2,080 | 1,725 | 718 | 755 | 1,076 | 884 | 866 | 1,033 | 959 | 807 | 710 |
| Inventory | 3.5% | 170 | 164 | 170 | 190 | 204 | 227 | 152 | 237 | 259 | 238 | 75.00 | 77.00 | 66.00 | 68.00 | 54.00 | 59.00 | 51.00 | 52.00 | 51.00 | 53.00 | 50.00 |
| Net PPE | 1.8% | 362 | 356 | 341 | 318 | 302 | 295 | 292 | 286 | 220 | 202 | 189 | 156 | 139 | 142 | 30.00 | 26.00 | 25.00 | 22.00 | 20.00 | 17.00 | 18.00 |
| Goodwill | 0% | 1,011 | 1,011 | 1,011 | 1,011 | 1,011 | 1,067 | 1,067 | 1,069 | 1,069 | 663 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 414 | 426 | 426 |
| Current Liabilities | 3.7% | 918 | 885 | 949 | 861 | 791 | 825 | 887 | 854 | 853 | 774 | 876 | 784 | 985 | 592 | 723 | 636 | 637 | 895 | 709 | 692 | 726 |
| LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 250 | - | - | - |
| Shareholder's Equity | 4.2% | 5,311 | 5,096 | 5,072 | 5,034 | 4,946 | 4,818 | 4,672 | 4,450 | 4,074 | 3,855 | 4,025 | 3,797 | 2,362 | 2,188 | 2,185 | 1,556 | 1,521 | 1,504 | 1,190 | 1,051 | 987 |
| Retained Earnings | 19.7% | 772 | 645 | 590 | 606 | 584 | 523 | 319 | 145 | -181 | -339 | -215 | -406 | -699 | -619 | -605 | -1,198 | -1,216 | -1,211 | -1,178 | -1,414 | -1,440 |
| Additional Paid-In Capital | 1.6% | 4,522 | 4,449 | 4,474 | 4,425 | 4,381 | 4,315 | 4,373 | 4,311 | 4,260 | 4,200 | 4,246 | 4,209 | 3,068 | 2,814 | 2,798 | 2,761 | 2,744 | 2,722 | 2,375 | 2,338 | 2,307 |
| Shares Outstanding | 0.2% | 229 | 229 | 227 | 229 | 230 | 229 | 227 | 226 | 225 | 224 | 221 | 212 | 193 | 190 | 188 | 186 | 185 | 173 | 169 | 167 | 165 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -7.8% | 1,041 | 1,128 | 1,258 | 1,370 | 1,415 | 1,255 | 1,035 | 907 | 604 | 615 | 556 | 337 | 316 | 308 | 426 | 344 | 341 | 312 | 195 | 229 | 213 |
| Share Based Compensation | 7.8% | 208 | 193 | 182 | 186 | 196 | 205 | 219 | 203 | 179 | 151 | 147 | 138 | 126 | 120 | 91.00 | 95.00 | 105 | 115 | 115 | 121 | 126 |
| Cashflow From Investing | -5.8% | -142 | -135 | -134 | -121 | -231 | -305 | -2,994 | -3,022 | -2,902 | -2,975 | -464 | -411 | -393 | -234 | -17.86 | 26.00 | 40.00 | 38.00 | 28.00 | -1.87 | -13.54 |
| Cashflow From Financing | -2.6% | -334 | -326 | -347 | -177 | -91.16 | -109 | 1,470 | 1,465 | 2,392 | 2,413 | 905 | 913 | -70.57 | -350 | -290 | -293 | -227 | 9.00 | -16.60 | -45.53 | -46.09 |
| Buy Backs | - | - | - | 250 | 454 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
HZNP Income Statement
2023-06-30Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) - USD ($) | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net sales | $ 944,959,000 | $ 876,411,000 | $ 1,777,018,000 | $ 1,761,656,000 |
| Cost of goods sold | 219,958,000 | 230,216,000 | 428,521,000 | 445,278,000 |
| Gross profit | 725,001,000 | 646,195,000 | 1,348,497,000 | 1,316,378,000 |
| OPERATING EXPENSES: | ||||
| Research and development | 150,035,000 | 103,246,000 | 284,183,000 | 206,378,000 |
| Selling, general and administrative | 434,125,000 | 398,221,000 | 887,479,000 | 770,955,000 |
| Impairment of goodwill | 0 | 56,171,000 | 0 | 56,171,000 |
| Gain on sale of asset | (2,000,000) | (2,000,000) | ||
| Total operating expenses | 582,160,000 | 557,638,000 | 1,169,662,000 | 1,033,504,000 |
| Operating income | 142,841,000 | 88,557,000 | 178,835,000 | 282,874,000 |
| OTHER EXPENSE, NET: | ||||
| Interest expense, net | (12,098,000) | (21,409,000) | (27,638,000) | (42,665,000) |
| Foreign exchange gain | 326,000 | 28,000 | 417,000 | 448,000 |
| Other income (expense), net | 4,183,000 | (2,389,000) | 2,840,000 | (3,131,000) |
| Total other expense, net | (7,589,000) | (23,770,000) | (24,381,000) | (45,348,000) |
| Income before expense (benefit) for income taxes | 135,252,000 | 64,787,000 | 154,454,000 | 237,526,000 |
| Expense (benefit) for income taxes | 8,181,000 | 3,813,000 | (27,301,000) | (27,709,000) |
| Net income | $ 127,071,000 | $ 60,974,000 | $ 181,755,000 | $ 265,235,000 |
| Net income per ordinary share—basic | $ 0.56 | $ 0.27 | $ 0.80 | $ 1.16 |
| Weighted average ordinary shares outstanding—basic | 228,743,143 | 230,020,004 | 228,571,356 | 229,559,715 |
| Net income per ordinary share—diluted | $ 0.54 | $ 0.26 | $ 0.78 | $ 1.12 |
| Weighted average ordinary shares outstanding—diluted | 233,935,591 | 236,166,384 | 233,938,149 | 236,077,147 |
| OTHER COMPREHENSIVE INCOME (LOSS), NET OF TAX | ||||
| Foreign currency translation adjustments | $ 1,409,000 | $ (1,433,000) | $ 794,000 | $ (1,893,000) |
| Pension and other post-employment benefit plan remeasurements | 179,000 | (547,000) | 2,003,000 | (222,000) |
| Interest rate swap contracts designated as cash flow hedges | 13,339,000 | 2,011,000 | 6,287,000 | 2,011,000 |
| Other comprehensive income (loss) | 14,927,000 | 31,000 | 9,084,000 | (104,000) |
| Comprehensive income | $ 141,998,000 | $ 61,005,000 | $ 190,839,000 | $ 265,131,000 |
HZNP Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $ 2,464,623 | $ 2,352,833 |
| Restricted cash | 4,791 | 4,755 |
| Accounts receivable, net | 717,417 | 676,347 |
| Inventories, net | 170,325 | 169,559 |
| Prepaid expenses and other current assets | 564,808 | 449,349 |
| Total current assets | 3,921,964 | 3,652,843 |
| Property, plant and equipment, net | 362,326 | 340,509 |
| Developed technology and other intangible assets, net | 2,486,565 | 2,664,777 |
| In-process research and development | 810,000 | 810,000 |
| Goodwill | 1,010,538 | 1,010,538 |
| Deferred tax assets, net | 444,306 | 431,814 |
| Other long-term assets | 263,042 | 204,135 |
| Total assets | 9,298,741 | 9,114,616 |
| CURRENT LIABILITIES: | ||
| Accounts payable | 85,543 | 155,800 |
| Accrued expenses and other current liabilities | 496,669 | 457,557 |
| Accrued trade discounts and rebates | 319,469 | 319,780 |
| Long-term debt-current portion | 16,000 | 16,000 |
| Total current liabilities | 917,681 | 949,137 |
| LONG-TERM LIABILITIES: | ||
| Long-term debt, net | 2,541,458 | 2,546,837 |
| Deferred tax liabilities, net | 264,815 | 342,017 |
| Other long-term liabilities | 263,828 | 204,451 |
| Total long-term liabilities | 3,070,101 | 3,093,305 |
| COMMITMENTS AND CONTINGENCIES | ||
| SHAREHOLDERS’ EQUITY: | ||
| Ordinary shares, $0.0001 nominal value; 600,000,000 shares authorized at June 30, 2023 and December 31, 2022; 229,323,393 and 227,625,913 shares issued at June 30, 2023 and December 31, 2022, respectively; and 228,939,027 and 227,241,547 shares outstanding at June 30, 2023 and December 31, 2022, respectively | 23 | 23 |
| Treasury stock, 384,366 ordinary shares at June 30, 2023 and December 31, 2022 | (4,585) | (4,585) |
| Additional paid-in capital | 4,522,145 | 4,474,199 |
| Accumulated other comprehensive income | 21,612 | 12,528 |
| Retained earnings | 771,764 | 590,009 |
| Total shareholders’ equity | 5,310,959 | 5,072,174 |
| Total liabilities and shareholders' equity | $ 9,298,741 | $ 9,114,616 |
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.